Answers are grounded in this paper and cite their sources.
AIMS: This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real-world setting in Spain as part of the 13-country PIONEER REAL programme. MATERIALS AND METHODS: <7% at EOS, and treatment satisfaction. Selected outcomes were stratified (post hoc) by sodium-glucose cotransporter-2 inhibitor (SGLT2i) co-use and T2D duration. RESULTS: and ≥5% body weight reduction. Treatment satisfaction increased, and no new safety concerns were identified. CONCLUSIONS: Oral semaglutide treatment improved glycaemic control and reduced body weight in Spanish clinical practice. Early intervention and SGLT2i co-treatment were associated with more favourable outcomes.
No takes yet. Share an insight, caveat, or question.
Delgado et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: